4.8 Article

Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection

Journal

IMMUNITY
Volume 47, Issue 4, Pages 766-+

Publisher

CELL PRESS
DOI: 10.1016/j.immuni.2017.09.014

Keywords

-

Categories

Funding

  1. NIH Martin Delaney I4C [UM1 AI126603]
  2. Beat-HIV [UM1 AI126620]
  3. DARE [UM1 AI12661]
  4. NIH [43222, 1K99AI125065-01]
  5. Mathilde Krim Fellowship, amfAR
  6. National Natural Science Foundation of China [81672024]
  7. Guangdong Innovative and Entrepreneurial Research Team Program [2016ZT06S638]
  8. Joint-Innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou [201508020256]

Ask authors/readers for more resources

The latent reservoir for HIV-1 in resting memory CD4(+) T cells is the major barrier to curing HIV-1 infection. Studies of HIV-1 latency have focused on regulation of viral gene expression in cells in which latent infection is established. However, it remains unclear how infection initially becomes latent. Here we described a unique set of properties of CD4(+) T cells undergoing effector-to-memory transition including temporary upregulation of CCR5 expression and rapid downregulation of cellular gene transcription. These cells allowed completion of steps in the HIV-1 life cycle through integration but suppressed HIV-1 gene transcription, thus allowing the establishment of latency. CD4(+) T cells in this stage were substantially more permissive for HIV-1 latent infection than other CD4(+) T cells. Establishment of latent HIV-1 infection in CD4(+) T could be inhibited by viral-specific CD8(+) T cells, a result with implications for elimination of latent HIV-1 infection by T cell-based vaccines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cell Biology

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry

Zilun Li, Meixiu Peng, Pin Chen, Chenshu Liu, Ao Hu, Yixin Zhang, Jiangyun Peng, Jiang Liu, Yihui Li, Wenxue Li, Wei Zhu, Dongxian Guan, Yang Zhang, Hongyin Chen, Jiuzhou Li, Dongxiao Fan, Kan Huang, Fen Lin, Zefeng Zhang, Zeling Guo, Hengli Luo, Xi He, Yuanyuan Zhu, Linghua Li, Bingding Huang, Weikang Cai, Lei Gu, Yutong Lu, Kai Deng, Li Yan, Sifan Chen

Summary: The study indicates that impairment of the ACE2 pathway is a key factor in the metabolic complications caused by COVID-19. Through screening and experiments, the researchers identified imatinib, methazolamide, and harpagoside as compounds that can directly activate ACE2. These compounds can improve metabolic disturbances and inhibit viral entry.

CELL METABOLISM (2022)

Review Virology

Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas

Yu-Chan Yang, Hung-Chih Yang

Summary: Hepatitis B virus (HBV) infection remains a global public health issue, and the current antiviral therapy fails to cure it. CRISPR-mediated gene editing has emerged as a promising approach for HBV cure, but it faces challenges such as off-target effects and difficulty in finding conserved target sequences.

VIRUSES-BASEL (2022)

Article Cell Biology

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

Yaochang Yuan, Xiantao Zhang, Ran Chen, Yuzhuang Li, Bolin Wu, Rong Li, Fan Zou, Xiancai Ma, Xuemei Wang, Qier Chen, Jieyi Deng, Yongli Zhang, Tao Chen, Yingtong Lin, Shumei Yan, Xu Zhang, Congrong Li, Xiuqing Bu, Yi Peng, Changwen Ke, Kai Deng, Ting Pan, Xin He, Yiwen Zhang, Hui Zhang

Summary: A bivalent nanoparticle vaccine has been developed to address immune evasion caused by SARS-CoV-2 variants. Through different immunization strategies, this vaccine can induce strong neutralizing antibody response and provide full protection against infection with D614G or B.1.351 strains in mice and rhesus macaques. Furthermore, a booster dose of the bivalent vaccine can elicit cross-neutralizing antibodies against SARS-CoV-2 variants in individuals previously vaccinated with the D614G-specific vaccine.

CELL REPORTS (2022)

Article Gastroenterology & Hepatology

Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas

Ting-Yuan Lan, Yen-Chun Lin, Tai-Chung Tseng, Hung-Chih Yang, Jui-Hung Kao, Chiao-Feng Cheng, Tai-Ju Lee, Shang-Chin Huang, Cheng-Hsun Lu, Ko-Jen Li, Song -Chou Hsieh

Summary: In HBsAg-negative patients receiving rituximab for autoimmune diseases, the risk of HBV reactivation may exist. Older age, positive HBc antibody, undetectable hepatitis B surface antibody level at initiation, and higher rituximab dose may be associated with a higher risk of HBV reactivation.

GUT AND LIVER (2023)

Article Medicine, General & Internal

Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine

Wang-Huei Sheng, Si-Man Ieong, Pin-Hung Lin, Ming-Ju Hsieh, Hung-Chih Yang, Ching-Fu Pan, Tai-Ling Chao, Sui-Yuan Chang, Shan-Chwen Chang

Summary: The study investigated the immunogenicity and adverse events of the third dose of mRNA vaccines in healthy adults. The results showed that the third dose mRNA COVID-19 vaccines markedly enhanced cellular and humoral responses and were safe. Immunological responses and adverse events were higher in individuals receiving the full-dose mRNA-1273 vaccine compared to other groups.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2023)

Article Biochemistry & Molecular Biology

Chemical inhibition of DPP9 sensitizes the CARD8 inflammasome in HIV-1-infected cells

Kolin M. Clark, Josh G. Kim, Qiankun Wang, Hongbo Gao, Rachel M. Presti, Liang Shan

Summary: The sensitization of the CARD8 inflammasome to non-nucleoside reverse transcriptase inhibitors (NNRTIs) can be achieved through chemical inhibition of the negative regulator DPP9. The DPP9 inhibitor Val-boroPro (VbP) can kill HIV-1-infected cells without NNRTIs and synergize with NNRTIs to promote clearance of infected cells. This offers a promising strategy for enhancing NNRTI efficacy in eliminating HIV-1 reservoirs.

NATURE CHEMICAL BIOLOGY (2023)

Article Oncology

Optimizing survival benefit by surgical resection by the seven-eleven criteria in Barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the Milan criteria

Chian-Tzu Huang, Yu-Long Chu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao

Summary: This study aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC) -A/B HCC beyond the Milan criteria with survival benefit. The study found that patients with tumor burden beyond the up-to-7 criteria but within 3 tumors had better overall survival (OS) with SR compared to transarterial chemoembolization (TACE), suggesting that SR should be considered in resectable patients.

LIVER CANCER (2023)

Letter Surgery

Impact of expanding HOPE Act experience criteria on program eligibility for transplantation from donors with human immunodeficiency virus to recipients with human immunodeficiency virus

Mary G. Bowring, Jessica M. Ruck, Mitchell G. Bryski, William Werbel, Aaron A. R. Tobian, Allan B. Massie, Dorry L. Segev, Christine M. Durand

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

Article Microbiology

Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR

Ting Huang, Jinfeng Cai, Peipei Wang, Jiasheng Zhou, Haitao Zhang, Ziqi Wu, Jiacong Zhao, Zhanlian Huang, Kai Deng

Summary: Although ART can effectively suppress viral replication, it cannot cure HIV-1 infection due to viral latent reservoir. Block and lock strategy aims to silence viral reservoir and prevent viral rebound. Ponatinib, an FDA-approved drug, can repress HIV-1 reactivation and does not cause cytotoxicity or cell dysfunction. It inhibits proviral HIV-1 transcription by blocking the AKT-mTOR pathway.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Article Immunology

Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: A Noninvasive Screening Model for Additional Diagnostics

Nitipong Permpalung, Teresa Po-Yu Chiang, Robin K. Avery, Darin Ostrander, Kausik Datta, Dorry L. Segev, Christine M. Durand, Sean X. Zhang, Allan B. Massie, Kieren A. Marr

Summary: A retrospective study was conducted to investigate COVID-19-associated pulmonary aspergillosis (CAPA), which is likely underdiagnosed and lacks sensitive diagnostic tools. A CAPA prediction model was built using multivariable logistic regression analysis, and the performance of the model was assessed using the area under the receiver operating characteristic curve (AUC). The model identified several factors, such as age, intubation time, dexamethasone treatment, and underlying diseases, that were significantly associated with CAPA, resulting in an AUC of 0.75. Screening at a cutoff of =0.085, the model showed a sensitivity of 82%, specificity of 51%, positive predictive value of 18.6%, and negative predictive value of 95.3%.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Medicine, Research & Experimental

IL-15 enhances HIV-1 infection by promoting survival and proliferation of CCR5+CD4+T cells

Yuhao Li, Hongbo Gao, Kolin M. Clark, Liang Shan

Summary: HIV-1 primarily uses CCR5 as its coreceptor but can occasionally switch to a CXCR4-tropic virus during late-stage infection. CCR5+CD4+ T cells, which are abundant in viremic individuals and SIV-infected nonhuman primates, play a major role in virus production. The differentiation and survival of CCR5+CD4+ T cells are regulated by IL-15, suggesting potential implications for HIV-1 infection and the boosting of anti-HIV-1 immunity.

JCI INSIGHT (2023)

Review Infectious Diseases

Current practice and recommendations for management of hepatitis B virus in people living with HIV in Asia

Grace Chung-Yan Lui, Grace Lai-Hung Wong, Hung-Chih Yang, Wang-Huei Sheng, Sun Hee Lee

Summary: This article describes the prevalence, clinical practice, and management recommendations for people living with HIV-HBV co-infection in Asia. The study found that the prevalence of HIV and HBV co-infection is higher in Asia and varies significantly between different regions. Early screening and treatment are important in preventing complications. Additionally, HBV vaccination programs are effective in reducing co-infection rates.

HIV MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year

Nitipong Permpalung, Tao Liang, Shilpa Gopinath, Katrina Bazemore, Joby Mathew, Darin Ostrander, Christine M. Durand, Shmuel Shoham, Sean X. Zhang, Kieren A. Marr, Robin K. Avery, Pali D. Shah

Summary: This study found that respiratory viral infections are associated with chronic lung allograft dysfunction and mortality in lung transplant recipients. Secondary invasive fungal infections were also found to be prevalent in these patients and were associated with CLAD progression/death. Screening for fungal infections is crucial in this setting.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2023)

Letter Medicine, General & Internal

Two-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Donors With Hepatitis C Viremia to Recipients Without Hepatitis C Viremia: A Small Uncontrolled Trial

Niraj M. Desai, Sherry G. Leung, Jennifer D. Motter, Dorry L. Segev, Daniel Warren, Christine M. Durand

ANNALS OF INTERNAL MEDICINE (2023)

Article Biochemistry & Molecular Biology

A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD

Xiaofei Wang, Ao Hu, Xiangyu Chen, Yixin Zhang, Fei Yu, Shuai Yue, Arong Li, Junsong Zhang, Zhiwei Pan, Yang Yang, Yao Lin, Leiqiong Gao, Jing Zhou, Jing Zhao, Fang Li, Yaling Shi, Feng Huang, Xiaofan Yang, Yi Peng, Luoyang Tu, Huan Zhang, Huanying Zheng, Jun He, Hui Zhang, Lifan Xu, Qizhao Huang, Yongqun Zhu, Kai Deng, Lilin Ye

Summary: This study demonstrates an antibody that efficiently neutralizes both SARS-CoV-2 and its variants, providing insights for the development of universal vaccines.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

No Data Available